Zydus receives USFDA approval for hypertension drug combo Triamterene, Hydrochlorothiazide Capsules

The fixed dose combination of Triamterene and Hydrochlorothiazide is indicated for the treatment of hypertension or edema in patients who have developed hypokalemia (low serum potassium levels) on Hydrochlorothiazide alone.

Gujarat: Headquartered in Ahmedabad, drug major Zydus Cadila has received the final approval from the USFDA to market Triamterene and Hydrochlorothiazide Capsules USP (US RLD – DYAZIDE), 37.5 mg/25 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

Also Read: Zydus Cadila gets USFDA nod for Carbamazepine extended-release tablets

The fixed dose combination of Triamterene and Hydrochlorothiazide is indicated for the treatment of hypertension or edema in patients who have developed hypokalemia (low serum potassium levels) on Hydrochlorothiazide alone.

It is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked. This medication may be used alone or as an adjunct to other antihypertensive drugs.

The group now has 249 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

The company discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is working on creating healthier communities globally. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.

Also Read: Zydus Cadila gets USFDA nod for blood pressure drug